United Kingdom Growth Hormone Deficiency Market Insight
United Kingdom Growth Hormone Deficiency Market is growing at an 3.82% CAGR, driven by improved diagnostics, recombinant therapies
United Kingdom Growth Hormone Deficiency Market Insights Forecasts to 2035
- The United Kingdom Growth Hormone Deficiency Market Size Was Estimated at USD 252.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 3.82% from 2025 to 2035
- The United Kingdom Growth Hormone Deficiency Market Size is Expected to Reach USD 367.3 Million by 2035
Notable Insights for United Kingdom Growth Hormone Deficiency Market
- By therapy type, recombinant human growth hormone therapies dominated, accounting for approximately 85% share in 2024, supported by strong clinical efficacy and long-term treatment adoption.
- By patient group, pediatric patients held approximately 65% share, due to increasing early diagnosis of childhood growth disorders and NHS-supported treatment access.
- Approximately 1 in 4,000 to 10,000 children in the UK are affected by growth hormone deficiency, increasing demand for diagnostic and therapeutic services.
- Around 75% of diagnosed patients receive long-term hormone replacement therapy, while advanced injectable formulations continue gaining adoption for improved compliance.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Growth Hormone Deficiency Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Growth Hormone Deficiency Market
- Novo Nordisk
- Pfizer
- Eli Lilly and Company
- Merck KGaA
- Ferring Pharmaceuticals
- Sandoz
- Ipsen
- Ascendis Pharma
- Others
Recent Developments:
- In July 2025: Ascendis Pharma received FDA approval for Skytrofa in adult growth hormone deficiency, expanding once-weekly hormone therapy access and strengthening long-acting endocrine treatment adoption globally.
- In June 2025: NICE recommended Novo Nordisk’s Sogroya for children with growth hormone deficiency, providing a once-weekly injectable treatment alternative to daily hormone replacement therapies across the UK.
Market Segmentation:
United Kingdom Growth Hormone Deficiency Market, By Therapy Type
- Recombinant Growth Hormone Therapy
- Long-Acting Growth Hormone Therapy
- Combination Therapy
- Others
United Kingdom Growth Hormone Deficiency Market, By Route of Administration
- Subcutaneous
- Injectable
United Kingdom Growth Hormone Deficiency Market, By Patient Group
- Paediatric
- Adult
United Kingdom Growth Hormone Deficiency Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Growth Hormone Deficiency Market is expected to witness stable growth due to increasing endocrine disorder awareness, improved diagnostic capabilities, and expanding access to recombinant hormone therapies. Experts emphasize that long-acting growth hormone formulations will continue gaining traction, supported by better patient adherence and NHS treatment support. Advancements in pediatric endocrinology, precision diagnostics, and once-weekly injectable therapies are anticipated to drive innovation and strengthen market expansion through 2035.